Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

"Offering Zepbound single-dose vials […] through another ... Ro was launched (as Roman) in 2017 and initially focused on men's health issues like erectile dysfunction before expanding its ...

Discover how GLP-1 weight loss medications like Ozempic and Wegovy are linked to reduced risks of dementia heart disease and more—alongside potential side effects to consider ...

These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

In the face of abrupt weight loss, one of the most common consequences is hair loss, even after bariatric surgery. Losing ...

The American Heart Association notes that in middle-aged people, about 17% of women and 24% of men meet the diagnostic criteria for ... relatively new and have not been thoroughly researched. Zepbound ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

A judge is set to hear arguments about whether to honor the Department of Justice's request that corruption charges against ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...